Use of trastuzumab and pertuzumab with FOLFOXIRI as neoadjuvant therapy for HER2-positive resectable metastatic colorectal cancer: The first case report

Asian J Surg. 2024 Jul 24:S1015-9584(24)01508-2. doi: 10.1016/j.asjsur.2024.07.136. Online ahead of print.

¹ Department of Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, Chongqing, 400030, China; Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, 400030, China.
² Department of Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, Chongqing, 400030, China.
³ Department of Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, Chongqing, 400030, China. Electronic address: sunhao_med@cqu.edu.cn.

No abstract available

Keywords: HER2-positive; Metastatic colorectal cancer; Neoadjuvant treatment; Pathologic complete response.

Publication types